Over the past few months, against the backdrop of a deadly pandemic, a series of horrifying injustices have been committed against Black Americans by the police. These tragic events have precipitated a large, global uprising against the systemic racism that permeates all of modern society, including science. To rebuild a better society, we need to rethink our own roles, both at the personal and professional level. We pledge solidarity with the Black Lives Matter movement, but we know that this is not sufficient to introduce real change. Together with the other journals of *The Lancet* family, we commit to turn this pledge into action.

In academia, lack of diversity and structural racism are heavily intertwined. According to statistics from the US National Center for Science and Engineering, in 2016, underrepresented minorities represented only 22% of bachelor\'s degree awardees, 13% of master\'s degree awardees, and less than 9% of awarded doctorates, while minorities constituted together 32.9% of the general population. The reasons behind these numbers are complex and multifactorial. Among them, one might be the shortage of role models: in 2014, in *American Economic Review*, Robert Fairlie and colleagues (University of California, CA, USA, and University of Toronto, ON, Canada) showed that students from minority backgrounds tend to perform better if the instructor is also from an underrepresented group.

Even if they decide to pursue an academic career, scientists who are Black encounter difficulties in securing major long-term funding. In 2011, a review of racial differences in the National Institutes of Health (NIH) research awards, which was published in *Science* by Donna Ginther and colleagues (University of Kansas \[KS, USA\], Clarivate Analytics \[PA, USA\], and NIH \[MD, USA\]), indicated that African-American principal investigators (PIs) were 12 percentage points less likely to receive funding for the most common type of research grant, a R01 grant, compared with white counterparts (the probability of being funded being 17% for Black PIs *vs* 29% for white PIs) . These authors further analysed the possible causes and, in their 2018 paper published in *PLoS One,* identified that Black applicants reported fewer publications, fewer citations, and published in journals that had a lower impact factor than white counterparts, explaining in part the observed inequalities in funding. In a study published in *Science Advances* in May, 2020, Elena Erosheva and colleagues (University of Washington, WA, USA) reported a similar funding gap for the years 2014--16 to that reported in 2011. As a scientific journal, it is crucial that we are mindful of diversity and that we are inclusive when commissioning written pieces, inviting peer-reviewers, and recruiting advisory board members. We fully commit to this aim and join a large group of impassioned allies who have done the same. However, we are acutely aware that simply aiming to be more diverse tackles only one part of this problem.

The hashtag \#BlackInTheIvory is currently trending on Twitter, highlighting the hurdles faced by Black academics and calling for specific actions from institutions. Countless stories of academic racism and racist microaggressions at conferences, in laboratories, and during interviews have been shared. A Twitter hashtag might help to begin to expose the extent and gravity of racism in academia. However, this is only the beginning of our collective education on academic racism. We urge further recounting and documentation for the cultural record. *EBioMedicine* offers a Letter format through which voices and calls for action can be highlighted. For example, in December 2019, Essi Viding (University College London, London, UK) published a Letter urging our readers that "We need diversity to accelerate scientific discovery" and proposed solutions. This Letter was part of a series of powerful Letters from another group facing challenges in academia: women. As a first step towards action, we encourage Letter proposals from Black, Asian, and minority ethnic authors to further the conversation surrounding bias and discrimination in academia.

As a journal, we can help to ensure that the papers we publish reflect the diversity of our societies and the challenges faced by different communities around the globe. The COVID-19 pandemic is a sobering reminder that ethnic minorities suffer from higher rates of poverty (more than 20% for Black and Native American people compared with 10% for white people in 2018 according to Poverty USA), and are disproportionately more susceptible to severe disease than white people. Even though the statistics reported in 2019 by the American Cancer Society (*CA: A Cancer Journal for Clinicians)* indicated a promising decline in the mortality gap between Black and white patients (from 33% in 1993 to 15% in 2016), the Black community still presents the highest mortality rate. These disparities in outcome, also observed in other diseases, could be attributed in part to inequalities in access to health care.

Stark differences are also apparent in maternal health outcomes: in the UK, 40 deaths related to pregnancy per 100 000 Black women were reported in the MBRRACE-UK (Mothers and Babies: Reducing Risk through Audits and Confidential Enquiries across the UK) 2018 report compared and only eight per 100 000 white women. The situation is similar in the USA, with 43 deaths related to pregnancy per 100 000 Black women versus 13 per 100 000 white women according to the Centers for Disease Control and Prevention 2019 report led by Wanda Berfield (GA, USA). In addition, scientific advances seen as progress in the biomedical community (eg, artificial intelligence (AI)-assisted diagnosis or personalised medicine) might only benefit a particular subset of the population. It has also been pointed out in an article on automated melanoma detection from 2018 in *JAMA Dermatology* by Adewole Adamson and Avery Smith (University of North Carolina, NC, USA, and University of Texas, TX, USA, Software Engineering from Baltimore, MD, USA) that AI tools might exacerbate racial health inequalities if not developed carefully. By using guidelines and standardised reporting checklists, we can ensure that minority populations are also enrolled in clinical trials and that the new tools and treatments presented in our journal are tested and validated in populations that are representative of the society.

We commit to ongoing discussion and welcome feedback from our community on how we can contribute meaningfully to equality and diversity in science. We understand these words and proposed actions should not lead to complacency and that real change will only happen if we continue to reflect and act on how our own personal biases impede social justice and scientific progress.
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